SHERIDAN, WYOMING – May 27, 2025 – Roche has received FDA approval for Susvimo® (ranibizumab injection) 100 mg/mL as a new treatment for diabetic retinopathy (DR), marking a pivotal advancement in the battle against this vision-threatening condition that affects nearly 10 million Americans.
SHERIDAN, WYOMING – May 27, 2025 – Roche has announced FDA approval of its VENTANA® MET (SP44) RxDx Assay, marking a major milestone in companion diagnostics for non-small cell lung cancer (NSCLC). This approval paves the way for a more precise identification of patients eligible for AbbVie’s Emrelis™ (telisotuzumab vedotin-tllv), a targeted therapy for non-squamous NSCLC with MET protein overexpression.
Enhancing Treatment Precision in Lung Cancer Care
SHERIDAN, WYOMING – May 27, 2025 – Roche has introduced its Elecsys® PRO-C3 diagnostic test, marking a major step forward in the assessment of liver fibrosis severity, particularly in patients with metabolic dysfunction–associated steatotic liver disease (MASLD). With the ability to deliver results in just 18 minutes, the new test is poised to streamline diagnostics and enable earlier, more accurate clinical decision-making.
Strategic Response to a Global Health Burden
SHERIDAN, WYOMING – May 17, 2025 – Danaher Corporation has achieved a historic milestone in genomic medicine, enabling the development and delivery of the world’s first personalized mRNA-based CRISPR therapy for an infant with a life-threatening genetic disorder—in under six months. Powered by the Danaher Business System (DBS), this breakthrough exemplifies how disciplined innovation and cross-company collaboration can dramatically accelerate biopharmaceutical timelines and patient impact.
Compressing an 18-Month Timeline into Six
SHERIDAN, WYOMING – May 8, 2025 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today introduced the Elecsys® PRO-C3 test, a groundbreaking diagnostic solution designed to assess liver fibrosis severity in patients with metabolic dysfunction–associated steatotic liver disease (MASLD). This innovative test, developed in partnership with Nordic Bioscience, provides healthcare providers with a fast and efficient way to evaluate liver fibrosis, a disease that contributes to one in every 25 deaths globally.
SHERIDAN, WYOMING – May 8, 2025 – Roche has achieved a significant milestone in oncology diagnostics with the U.S. Food and Drug Administration (FDA) granting Breakthrough Device Designation for its VENTANA® TROP2 (EPR20043) RxDx Device. This marks the first FDA recognition for a computational pathology companion diagnostic (CDx) device using artificial intelligence, highlighting Roche's continued leadership in cancer diagnostics and precision medicine.
SHERIDAN, WYOMING – May 8, 2025 – Thermo Fisher Scientific Inc. (NYSE: TMO), a global leader in serving science, has announced that Marc N. Casper, the company’s chairman, president, and chief executive officer, will be presenting at the highly anticipated BofA Securities 2025 Health Care Conference on Tuesday, May 13, 2025, at 11:40 a.m. (ET). The presentation will be available via a live webcast, accessible through the Investors section of Thermo Fisher’s official website.
SHERIDAN, WYOMING – May 08, 2025 – Agilent Technologies Inc. (NYSE: A) has introduced its highly anticipated Seahorse XF Flex Analyzer, an advanced, high-performance 24-well system designed to propel metabolic analysis in complex 3D tissue and organoid models. This groundbreaking tool, accompanied by dedicated consumables and kits, promises to transform the way researchers study cellular metabolism, providing critical insights into disease mechanisms and therapeutic development.
SHERIDAN, WYOMING – May 8, 2025 – Agilent Technologies Inc. (NYSE: A) is set to highlight its groundbreaking solutions and strategic collaborations at the upcoming American Association for Cancer Research (AACR) Annual Meeting in Chicago, Illinois, from April 25-30, 2025. Agilent’s innovative products, including advanced DNA cancer panels, multiomic profiling assays, and cutting-edge companion diagnostics, will take center stage, reflecting the company’s commitment to advancing cancer research and therapeutic development.
SHERIDAN, WYOMING – May 8, 2025 – Agilent Technologies Inc. (NYSE: A) has announced that its PD-L1 IHC 22C3 pharmDx (Code SK006) assay has achieved European IVDR certification. This certification positions the assay as a Companion Diagnostic (CDx) to identify gastric or gastroesophageal junction (GEJ) adenocarcinoma patients eligible for treatment with KEYTRUDA® (pembrolizumab), a leading anti-PD-1 therapy developed by Merck.